Yingda Xu (VP)
Responsible for quality analysis. Doctor of Michigan State University, USA, Postdoctoral of University of Texas Southwestern Medical Center. Yingda has published more than 20 SCI papers, and presented reports at international conferences such as PEGS and AET several times. As senior researcher in Bristol-Myers Squibb Company (BMS), Yingda was responsible for analysis and development of Orencia Post Marketing Commitment for the FDA. He successfully developed a tryptic peptide mapping method for the quantification of Orencia oxidative deamination products, and the application of this method in the batch release quality control environment was quickly verified. In 2008, he served as the R&D executive of Adimab company and established what is now known as the world's first-class antibody discovery platform by yeast display technology.